Enliven Therapeutics (ELVN) Amortizatization of Intangibles (2019 - 2026)
Enliven Therapeutics' (ELVN) quarterly Amortizatization of Intangibles came in at -$266000.0 in Q1 2026, down 691.11% year-on-year from $45000.0 in Q1 2025, and down 383.64% quarter-over-quarter from -$55000.0 in Q4 2025.
Enliven Therapeutics (ELVN) Amortizatization of Intangibles (2019 - 2026) Analysis & Trends
Enliven Therapeutics has disclosed Amortizatization of Intangibles across 8 years of filings, most recently posting -$266000.0 for Q1 2026.
- Amortizatization of Intangibles for Q1 2026 came in at -$266000.0, down 691.11% year-over-year; the trailing twelve-month figure through Mar 2026 was -$84000.0 (up 91.92% YoY), and the FY2025 annual result was $227000.0, up 153.54% from the prior year.
- Amortizatization of Intangibles came in at -$266000.0 for Q1 2026 at Enliven Therapeutics, down from -$55000.0 in the prior quarter.
- In the past five years, Amortizatization of Intangibles ranged from a high of $2.0 million in Q3 2023 to a low of -$976000.0 in Q4 2024.
- The 5-year median for Amortizatization of Intangibles is $46500.0 (2022), against an average of $295714.3.
- Across the five-year window, Amortizatization of Intangibles surged 1631.25% in 2023 and tumbled 691.11% in 2026, its largest moves.
- Enliven Therapeutics' Amortizatization of Intangibles stood at $48000.0 in 2022, then soared by 3625.0% to $1.8 million in 2023, then tumbled by 154.59% to -$976000.0 in 2024, then surged by 94.36% to -$55000.0 in 2025, then plunged by 383.64% to -$266000.0 in 2026.
- The last three Amortizatization of Intangibles figures came in at -$266000.0 (Q1 2026), -$55000.0 (Q4 2025), and $310000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | 13,267.00 |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | - |
| 10 | Enliven Therapeutics | 2.32 Bn | 2.32 Bn | - | -266,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -266,000.00 |
| Mar 31, 2026 | -266,000.00 |
| Dec 31, 2025 | -55,000.00 |
| Dec 31, 2025 | -55,000.00 |
| Sep 30, 2025 | 310,000.00 |
| Sep 30, 2025 | 310,000.00 |
| Jun 30, 2025 | -73,000.00 |
| Jun 30, 2025 | -73,000.00 |
| Mar 31, 2025 | 45,000.00 |
| Mar 31, 2025 | 45,000.00 |
| Dec 31, 2024 | -976,000.00 |
| Dec 31, 2024 | -976,000.00 |
| Sep 30, 2024 | -712,000.00 |
| Sep 30, 2024 | -712,000.00 |
| Jun 30, 2024 | 603,000.00 |
| Jun 30, 2024 | 603,000.00 |
| Mar 31, 2024 | 661,000.00 |
| Mar 31, 2024 | 661,000.00 |
| Dec 31, 2023 | 1.79 Mn |
| Dec 31, 2023 | 1.79 Mn |